ARMPArmata Pharmaceuticals, Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $4.07 · now $4.07 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, ARMP has typically landed between $2.73 and $6.23 — a range of −33.0% to +53.0% from the issuance price $4.07.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

4,993 overlapping 1 month windows · 2006-09-262026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($4.07) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where ARMP has typically landed a month from the 2026-09-16 close of $4.07 — the range is history, not a prediction.

$2.73worst · -33.0%$6.23best · +53.0%
  • now $4.07 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $4.03 (-0.9%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $3.44$4.63
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $2.73$6.23
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 4,993 windows spanning 2006-09-26 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2017-04-24−77.0%−77.0%+0.0%
2017-04-25−76.6%−76.6%+0.0%
2017-04-17−75.1%−75.1%+0.0%
3 best
2013-06-24+343.8%+0.0%+343.8%
2013-06-26+306.3%+0.0%+343.8%
2013-06-25+306.3%+0.0%+343.8%

4,993 overlapping windows · 2006-09-262026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~20 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
55%
+9.2%
n=20
Feb
55%
+3.0%
n=20
Mar
45%
+2.8%
n=20
Apr
35%
−2.6%
n=20
May
35%
−9.1%
n=20
Jun
50%
−0.8%
n=20
Jul
45%
+12.5%
n=20
Aug
35%
+1.9%
n=20
Sep
35%
−7.6%
n=20
Oct
40%
−5.0%
n=20
Nov
50%
+9.6%
n=20
Dec
20%
−6.9%
n=20

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$15$2↑ buys↓ sales
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

26 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-07-10Birx DeborahdirectorWithheld for tax14,041198,417Form 4
2026-04-24Gilmer Daniel B.directorAward / grant51,28051,280Form 4
2026-03-14Birx DeborahdirectorWithheld for tax4,919212,458Form 4
2026-03-14Kyme PierreofficerWithheld for tax1,0309,461Form 4
2026-03-09Haimovitz JulesdirectorAward / grant25,64025,640Form 4
2026-03-09Birx DeborahdirectorAward / grant421,226421,226Form 4
2026-03-09Odysseas Kostas DdirectorAward / grant25,64025,640Form 4
2026-03-09Peterson Todd C.directorAward / grant25,64025,640Form 4
2026-03-09PATTI JOSEPH MdirectorAward / grant25,64025,640Form 4
2026-03-09House David DuaneofficerAward / grant109,885109,885Form 4
2026-03-09Kyme PierreofficerAward / grant183,142183,142Form 4
2026-03-09Kramer RobindirectorAward / grant25,64025,640Form 4
2026-03-09Schlesinger Sarah J.directorAward / grant25,64025,640Form 4
2025-07-10Birx DeborahdirectorWithheld for tax13,637217,377Form 4
2025-03-14Birx DeborahdirectorWithheld for tax6,061231,014Form 4
2025-03-14Kyme PierreofficerWithheld for tax1,02710,491Form 4
2025-02-05Birx DeborahdirectorAward / grant240,000240,000Form 4
2025-02-05PATTI JOSEPH MdirectorAward / grant54,34354,343Form 4
2025-02-05Peterson Todd C.directorAward / grant54,34354,343Form 4
2025-02-05House David DuaneofficerAward / grant25,00025,000Form 4
2025-02-05Schlesinger Sarah J.directorAward / grant54,34354,343Form 4
2025-02-05Haimovitz JulesdirectorAward / grant54,34354,343Form 4
2025-02-05Kramer RobindirectorAward / grant54,34354,343Form 4
2025-02-05Kyme PierreofficerAward / grant100,000100,000Form 4
2025-02-05Odysseas Kostas DdirectorAward / grant54,34354,343Form 4
2024-07-10Birx DeborahdirectorWithheld for tax22,925237,075Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.